Duchenne Muscular Dystrophy (DMD) Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Duchenne muscular dystrophy (DMD)
is a genetic disorder characterized by progressive muscle degeneration and
weakness. DMD is caused due to alteration in gene sequence coding for
dystrophin protein, which is present the muscle. It is a rare muscle disease
which majorly affects males. The symptoms includes intellectual disability,
muscle weakness and, difficulty in walking and breathing. Congestive heart failure, mental impairment,
pneumonia or respiratory failure are some of the complications of this disease.
The treatment is available to control or reduce the signs and symptoms as DMD
is not curable. Steroid drugs are used to control the symptoms of duchenne
muscular dystrophy. Stem cell therapy and gene therapy could be used for treatment
of this disease in future.
Growing investments in the
research and development, to find out effective treatment for DMD is driving
the growth of duchenne muscular dystrophy (DMD) treatment market
According to the reports of
Centers for Disease Control and prevention (CDC) 2007, 349 out of 2.37 million
males in the United States were reported to be suffering from DMD. Whereas in
2019, 349 new cases of DMD were reported.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/898
Increasing incidences of DMD and
requirement for its treatment is driving the growth of duchenne muscular
dystrophy treatment market. Various organizations are involved in spreading
awareness and investing in research and development to find the effective
treatment for this disease, which is contributing to the growth of duchenne
muscular dystrophy treatment market. For instance, Muscular Dystrophy
Association (MDA), U.S. invests 75000 USD in research and development to find
out the treatment for duchenne muscular dystrophy and the association funds more
than 150 care centers, health care facility centers, and hospitals across U.S.
and other countries. Moreover, other factors, such as constant research on stem
cell therapy, gene therapy, and exon skipping drugs for the treatment of DMD is
expected to propel the growth of DMD treatment market. However, major
restraints hampering the growth of duchenne muscular dystrophy treatment market
are, low seeking rate due to prognosis and late diagnosis of this disease.
Rising hospitalization for DMD is
the factor helping the hospital segment to hold the maximum share in duchenne
muscular dystrophy (DMD) treatment market
Growing patient population in
North America and Europe is the factor contributing to the growth of duchenne
muscular dystrophy (DMD) treatment market in these regions
Regional segmentation of Duchenne
muscular dystrophy (DMD) treatment market by Coherent Market Insights comprises
of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America dominates in the duchenne muscular dystrophy treatment market,
due well-established healthcare facilities in this region.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/duchenne-muscular-dystrophy-treatment-market-898
Europe contributes to the growth
of duchenne muscular dystrophy treatment market followed by North America, due
to high rate of affected population in this region. For instance, according to
Center for Disease Control and Prevention (CDC), in North England, 233 out of
1.49 million male patients were reported for DMD or other muscular dystrophy
cases in 2009.
Key players are involved in the
research and development of novel drug therapy for the treatment of duchenne
muscular dystrophy (DMD)
Key players operating duchenne
muscular dystrophy (DMD) treatment market includes SUMMIT Therapeutics Plc.,
PTC Therapeutics, BioMarin Pharmaceuticals Incorporated, Sarepta Therapeutics,
Pfizer Incorporated, Pharmacia & Upjohn LLC, and others. Major industry
players are involved in the research and development of novel drugs for
treatment, and strategies such as collaboration and partnership are adopted by
companies to hold the major share in the duchenne muscular dystrophy (DMD)
treatment market. For instance, PTC Therapeutics International Limited has
obtained conditional approval and orphan drug designation in 2014 for
Translarna, which is a novel gene therapy for the treatment of duchenne
muscular dystrophy.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/898
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200 Seattle,
WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment